Phaseline

Companies › LXO Ireland

LXO Ireland: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 3; Other; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cocaine
Sodium channel alpha subunit blocker
Ion channelsPhase 3ENT DisorderDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04792034CocainePhase 3ENT DisorderOtherDec 2027
NCT04792034CocainePhase 3ENT DisorderOtherDec 2027

Targets

Ion channels (1)

Companies with the same targets

Xenon Pharmaceuticals Praxis Precision Medicines HB BioTech Encoded Therapeutics Biohaven Therapeutics TLC Biopharmaceuticals Shenzhen Ausa Pharmed Grace Therapeutics Jiangsu HengRui Medicine Industrial Farmacéutica Cantabria

Companies built like this

Soleno Therapeutics Acer Therapeutics Shanghai Haiyan Pharmaceutical Technology Kaken Pharmaceutical Spine BioPharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.